Provided by Tiger Fintech (Singapore) Pte. Ltd.

Longeveron Inc

1.67
-0.0100-0.60%
Post-market: 1.680.0100+0.60%19:51 EDT
Volume:281.50K
Turnover:460.32K
Market Cap:25.07M
PE:-0.82
High:1.70
Open:1.66
Low:1.58
Close:1.68
Loading ...

Longeveron management to meet with Roth MKM

TIPRANKS
·
11 Jun

Director’s Major Stock Sale Shakes Up Longeveron!

TIPRANKS
·
03 Jun

Director Rock Soffer Reports Disposal of Common Shares in Longeveron Inc

Reuters
·
28 May

Longeveron Q1 EPS $(0.34) Misses $(0.30) Estimate, Sales $381.00K Miss $608.25K Estimate

Benzinga
·
09 May

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

GlobeNewswire
·
02 May

BRIEF-Longeveron Says Board Confirms Cash-To-Equity Program Approval - SEC Filing

Reuters
·
01 May

Longeveron Inc - on Apr 24 , Board Confirms Cash-to-Equity Program Approval - SEC Filing

THOMSON REUTERS
·
01 May

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

GlobeNewswire
·
23 Apr

Longeveron Files $70 Million Mixed Shelf

MT Newswires Live
·
29 Mar

BRIEF-Longeveron Inc Files For Mixed Shelf Of Up To $70 Million - SEC Filing

Reuters
·
29 Mar

Longeveron Inc Files for Mixed Shelf of up to $70 Mln - SEC Filing

THOMSON REUTERS
·
29 Mar

Longeveron’s Promising Alzheimer’s Program: Buy Rating Backed by FDA Alignment and Strategic Advancements

TIPRANKS
·
22 Mar

Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Mar

Longeveron Inc: Company Anticipates Initiating Pivotal Clinical Trial in Second Half of 2026

THOMSON REUTERS
·
20 Mar

Longeveron® Announces Positive Type B Meeting With U.S. FDA Regarding Pathway to Bla for Laromestrocel (Lomecel-Btm) in Alzheimer’s Disease

THOMSON REUTERS
·
20 Mar

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

GlobeNewswire
·
20 Mar

LGVN Announces Positive Alzheimer’s News

Zacks Small Cap Research
·
20 Mar

Roth MKM Keeps Their Buy Rating on Longeveron (LGVN)

TIPRANKS
·
12 Mar

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease

Reuters
·
11 Mar

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

GlobeNewswire
·
11 Mar